The independent Institute for Quality and Efficiency in Health Care (IQWiG) has released an addendum to its evaluation of Sotatercept for treating pulmonary arterial hypertension (PAH) in adults. The assessment, commissioned by the Federal Joint Committee (G-BA), concludes that Sotatercept does not demonstrate an added benefit over existing therapies for PAH patients classified under WHO Functional Class II to III.
Study Evaluation Highlights Key Findings
IQWiG’s evaluation focused on the STELLAR randomized controlled trial, which compared Sotatercept with a placebo in improving exercise capacity among PAH patients. Despite some improvements in specific subgroups, the overall benefit of Sotatercept remains unproven. The study revealed significant differences favoring Sotatercept in patients with WHO Functional Class III, particularly in walking distance and cardiovascular symptoms. However, these benefits were not deemed clinically relevant for patients with Class II.
Adverse Effects Raise Concerns
The analysis also identified notable adverse effects associated with Sotatercept. Participants receiving the drug reported higher instances of eye disorders and nosebleeds compared to the placebo group. These side effects contribute to the cautious stance taken by IQWiG, as the risks may outweigh the unestablished benefits. The report emphasizes the importance of considering these adverse events in the overall assessment of Sotatercept’s efficacy and safety.
• Sotatercept showed statistically significant improvements in certain PAH subgroups.
• Increased risk of eye disorders and nosebleeds reported with Sotatercept use.
• Overall benefit not sufficient to justify additional use over standard therapies.
The findings suggest that while Sotatercept may offer some advantages for specific patient groups, the lack of a clear overall benefit combined with the potential for serious side effects limits its viability as a standard treatment option. Healthcare providers are advised to weigh these factors carefully when considering Sotatercept for PAH patients.
Sotatercept’s approval and inclusion in treatment guidelines remain uncertain pending further evidence. Patients and clinicians must stay informed about ongoing research and emerging data that could influence future recommendations. The comprehensive evaluation by IQWiG underscores the critical balance between therapeutic benefits and safety in managing complex conditions like pulmonary arterial hypertension.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
